June 2009: PDS Biotechnology completes relocation of its drug development operations to Indiana. The company’s headquarters is located in the city of Lawrenceburg 15 minutes from the Cincinnati International airport and between the cities of Cincinnati and Indianapolis.

May 2009: PDS Biotechnology completes NIH-sponsored study to develop a treatment for Melanoma. The drug containing 3-melanoma peptides demonstrated the versatility and potency of the VersamuneTM technology in treating cancer. Optimization of the formulation is on-going.

February 2009: PDS Biotechnology Corporation finalizes commercial licensing agreement with Merck EPROVA AG. PDS Biotechnology has obtained an exclusive license from Merck Eprova AG to utilize Merck’s proprietary chiral lipid DOTAP Chloride in PDS Biotechnology’s Versamune™–based products. PDS Biotechnology will own the intellectual property rights to products.

January 2009: PDS Biotechnology completes $2.75 Million preclinical funding round. PDS Biotechnology completed a $2.75 million funding round with a $2.0 M grant from the IEDC and a $0.75 M investment by the company’s lead investor, Asklepios Capital, LLC and the Sherrie Labrum trust.

October 2008: The US National Cancer Institute has notified PDS Biotechnology of a contract award to perform pre-IND animal toxicology studies for Versamune™ –HPV, an immunotherapy being developed to treat cervical cancer and other HPV-related cancers and infections.

Welcome to PDS Biotechnology Corporation

Simple, safe and innovative immunotherapies targeting infectious diseases and cancer

PDS Biotechnology Corporation is a biopharmaceutical company applying the company’s platform Versamune™ nanotechnology to a new class of safe, simple, potent and targeted immunotherapies for the treatment of cancer and infectious diseases.

Unlike typical vaccines which are only preventative, the patented Versamune™ nanoparticle leads to potent curative and preventative immune responses. The nanoparticles facilitate the uptake of disease-associated proteins and peptides by the cells of the immune system and simultaneously activate the immune system to generate a strong and specific immune response against the specific infected cells in the body, resulting in eradication of the cancer or viral disease. Superior prevention and cure of cancer has been demonstrated in head-to-head studies with the leading technologies. In preclinical studies, both Versamune™-HPV and Versamune™-Melanoma, being developed to treat cancers caused by infection with the HPV virus and melanoma respectively have demonstrated superior efficacy in causing tumor eradication. Ongoing NIH sponsored GLP toxicology studies have also demonstrated a very safe drug profile even at very high doses far exceeding the therapeutic dose.

Immunotherapies have been shown to provide significant potential in treating some of the most debilitating cancers and infectious diseases. However, the current technologies suffer from several drawbacks including high complexity and cost, as well as low potency and safety. The Versamune™ technology provides the solution.

The first Versamune™-based product, Versamune™-HPV will enter human clinical trials in 2010.

The company's mission is to utilize its proprietary technology to pioneer the development of safe, simple and cost effective immunotherapies to treat and prevent specific cancers and infectious diseases for which no cures exist.